menu
    • menu
    [{"orgOrder":0,"company":"Kathmandu University","sponsor":"Asian Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Sodium Valproate","moa":"Succinate semialdehyde dehydrogenase","graph1":"Neurology","graph2":"Phase IV","graph3":"Kathmandu University","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"Kathmandu University \/ Asian Pharmaceuticals","highestDevelopmentStatusID":"11","companyTruncated":"Kathmandu University \/ Asian Pharmaceuticals"},{"orgOrder":0,"company":"Cereno Scientific","sponsor":"Worldwide Clinical Trials","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SWEDEN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Sodium Valproate","moa":"Succinate semialdehyde dehydrogenase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Cereno Scientific","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Cereno Scientific \/ Worldwide Clinical Trials","highestDevelopmentStatusID":"8","companyTruncated":"Cereno Scientific \/ Worldwide Clinical Trials"},{"orgOrder":0,"company":"Australasian Gastro-Intestinal Trials Group","sponsor":"Olivia Newton-John Cancer Research Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Sodium Valproate","moa":"Succinate semialdehyde dehydrogenase","graph1":"Oncology","graph2":"Phase II","graph3":"Australasian Gastro-Intestinal Trials Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Australasian Gastro-Intestinal Trials Group \/ Olivia Newton-John Cancer Research Institute","highestDevelopmentStatusID":"8","companyTruncated":"Australasian Gastro-Intestinal Trials Group \/ Olivia Newton-John Cancer Research Institute"},{"orgOrder":0,"company":"Desitin Arzneimittel","sponsor":"BioPharma Services","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"GERMANY","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Sodium Valproate","moa":"Succinate semialdehyde dehydrogenase","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Desitin Arzneimittel","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Desitin Arzneimittel \/ BioPharma Services","highestDevelopmentStatusID":"6","companyTruncated":"Desitin Arzneimittel \/ BioPharma Services"},{"orgOrder":0,"company":"Cerebral Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Sodium Valproate","moa":"Succinate semialdehyde dehydrogenase","graph1":"Neurology","graph2":"Phase II","graph3":"Cerebral Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intracerebroventricular Implant","sponsorNew":"Cerebral Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cerebral Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cerebral Therapeutics","sponsor":"Lynx1 Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Series C Financing","leadProduct":"Sodium Valproate","moa":"Succinate semialdehyde dehydrogenase","graph1":"Neurology","graph2":"Phase II","graph3":"Cerebral Therapeutics","amount2":0.040000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0.040000000000000001,"dosageForm":"Intracerebroventricular Implant","sponsorNew":"Cerebral Therapeutics \/ Lynx1 Capital Management","highestDevelopmentStatusID":"8","companyTruncated":"Cerebral Therapeutics \/ Lynx1 Capital Management"},{"orgOrder":0,"company":"Cerebral Therapeutics","sponsor":"RA Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Series B Financing","leadProduct":"Sodium Valproate","moa":"Succinate semialdehyde dehydrogenase","graph1":"Neurology","graph2":"Phase II","graph3":"Cerebral Therapeutics","amount2":0.040000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0.040000000000000001,"dosageForm":"Intracerebroventricular Implant","sponsorNew":"Cerebral Therapeutics \/ RA Capital Management","highestDevelopmentStatusID":"8","companyTruncated":"Cerebral Therapeutics \/ RA Capital Management"},{"orgOrder":0,"company":"Cereno Scientific","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SWEDEN","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Divalproex Sodium","moa":"||Succinate semialdehyde dehydrogenase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Cereno Scientific","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cereno Scientific \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cereno Scientific \/ Inapplicable"},{"orgOrder":0,"company":"Desitin Arzneimittel","sponsor":"BioPharma Services","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"GERMANY","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Sodium Valproate","moa":"Succinate semialdehyde dehydrogenase","graph1":"Undisclosed","graph2":"Phase I","graph3":"Desitin Arzneimittel","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Desitin Arzneimittel \/ BioPharma Services","highestDevelopmentStatusID":"6","companyTruncated":"Desitin Arzneimittel \/ BioPharma Services"}]

    Find Clinical Drug Pipeline Developments & Deals for Valproate Sodium

    Menu

    Valproate Sodium

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Sanofi

                            France
                            ChemOutsourcing
                            Attending
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

                            Lead Product(s) : Sodium Valproate

                            Therapeutic Area : Neurology

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study of Excretion Balance and Pharmacokinetics of [14C]-Sodium Valproate (3.7 MBq) in Healthy Postmenopausal ...

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            September 21, 2018

                            Lead Product(s) : Sodium Valproate

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            Sanofi Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Cereno Scientific

                            Sweden arrow
                            Coatings Trends
                            Not Confirmed

                            Cereno Scientific

                            Sweden arrow
                            Coatings Trends
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Divalproex Sodium,Sodium Valproate

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Cereno's HDAC Inhibitor Reduces Risks from PAH in Phase 2 Trial

                            Details : CS1 is an HDAC inhibitor that works through epigenetic modulation, being developed as a safe, effective and disease modifying treatment for pulmonary arterial hypertension.

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            September 30, 2024

                            Lead Product(s) : Divalproex Sodium,Sodium Valproate

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Desitin Arzneimittel

                            Germany arrow
                            Coatings Trends
                            Not Confirmed

                            Desitin Arzneimittel

                            Germany arrow
                            Coatings Trends
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sodium Valproate

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase I

                            Sponsor : BioPharma Services

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Bioavailability of Orfiril Long 500 mg Prolonged-Release Minitablets and Ergenyl Chrono 500 mg Prolonged-Relea...

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            January 19, 2024

                            Lead Product(s) : Sodium Valproate

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase I

                            Sponsor : BioPharma Services

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Desitin Arzneimittel

                            Germany arrow
                            Coatings Trends
                            Not Confirmed

                            Desitin Arzneimittel

                            Germany arrow
                            Coatings Trends
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sodium Valproate

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Sponsor : BioPharma Services

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Bioavailability and Food Effect of Sodium Valproate Minitablets in Healthy Subjects.

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            January 18, 2024

                            Lead Product(s) : Sodium Valproate

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Sponsor : BioPharma Services

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Australasian Gastro-Intestinal Trials Group

                            Country arrow
                            Coatings Trends
                            Not Confirmed

                            Australasian Gastro-Intestinal Trials Group

                            Country arrow
                            Coatings Trends
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sodium Valproate

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Olivia Newton-John Cancer Research Institute

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Combining Sodium Valproate With Standard-of-care EGFR (Epidermal Growth Factor Receptor) Monoclonal Antibody T...

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            January 23, 2023

                            Lead Product(s) : Sodium Valproate

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Olivia Newton-John Cancer Research Institute

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Kathmandu University

                            Country arrow
                            Coatings Trends
                            Not Confirmed

                            Kathmandu University

                            Country arrow
                            Coatings Trends
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sodium Valproate

                            Therapeutic Area : Neurology

                            Study Phase : Phase IV

                            Sponsor : Asian Pharmaceuticals

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Bioequivalence Study of Sodium Valproate and Valproic Acid Tablets

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            December 08, 2022

                            Lead Product(s) : Sodium Valproate

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase IV

                            Sponsor : Asian Pharmaceuticals

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Cerebral Therapeutics

                            U.S.A arrow
                            Coatings Trends
                            Not Confirmed

                            Cerebral Therapeutics

                            U.S.A arrow
                            Coatings Trends
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sodium Valproate

                            Therapeutic Area : Neurology

                            Study Phase : Phase II

                            Sponsor : Lynx1 Capital Management

                            Deal Size : $40.0 million

                            Deal Type : Series C Financing

                            DEALS_DEV arrow-down

                            Cerebral Therapeutics, Inc. Secures $40 Million Series C Financing

                            Details : The Company plans to use proceeds to complete an international Phase 2 double-blind, randomized, placebo-controlled clinical trial of its investigational drug Valproic Acid (CT-010) for the treatment of uncontrolled seizures in patients with medically re...

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            June 28, 2022

                            Lead Product(s) : Sodium Valproate

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II

                            Sponsor : Lynx1 Capital Management

                            Deal Size : $40.0 million

                            Deal Type : Series C Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Cereno Scientific

                            Sweden arrow
                            Coatings Trends
                            Not Confirmed

                            Cereno Scientific

                            Sweden arrow
                            Coatings Trends
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sodium Valproate

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase II

                            Sponsor : Worldwide Clinical Trials

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Effect of CS1 in Subjects With Pulmonary Arterial Hypertension

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            February 04, 2022

                            Lead Product(s) : Sodium Valproate

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase II

                            Sponsor : Worldwide Clinical Trials

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Cerebral Therapeutics

                            U.S.A arrow
                            Coatings Trends
                            Not Confirmed

                            Cerebral Therapeutics

                            U.S.A arrow
                            Coatings Trends
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sodium Valproate

                            Therapeutic Area : Neurology

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Cerebral Therapeutics Announces Enrollment of First Patient in a Multicenter Randomized Controlled Phase 2b Tr...

                            Details : The Phase 2b, randomized, placebo-controlled, double-blind study is designed to expand on positive results of the ongoing Phase 1b/2a study assessing the safety and efficacy of intracerebroventricular administration of sodium valproate.

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            November 17, 2020

                            Lead Product(s) : Sodium Valproate

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Cerebral Therapeutics

                            U.S.A arrow
                            Coatings Trends
                            Not Confirmed

                            Cerebral Therapeutics

                            U.S.A arrow
                            Coatings Trends
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sodium Valproate

                            Therapeutic Area : Neurology

                            Study Phase : Phase II

                            Sponsor : RA Capital Management

                            Deal Size : $35.0 million

                            Deal Type : Series B Financing

                            DEALS_DEV arrow-down

                            Cerebral Therapeutics Completes $35 Million Series B Financing

                            Details : The funding will help the company to initiate Phase 2b clinical trial for the treatment of medically refractory epilepsy in 2020.

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            July 01, 2020

                            Lead Product(s) : Sodium Valproate

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II

                            Sponsor : RA Capital Management

                            Deal Size : $35.0 million

                            Deal Type : Series B Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth